GLPG Galapagos NV

230.54
+0.26  (+0%)
Previous Close 230.28
Open 229.19
Price To Book 5.33
Market Cap 14,908,284,533
Shares 64,666,802
Volume 66,257
Short Ratio
Av. Daily Volume 138,693
Stock charts supplied by TradingView

NewsSee all news

  1. Orphan Drug Designation for GLPG1690 in systemic sclerosis

    Mechelen, Belgium; 29 January 2020, 8.00 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces today that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted

  2. Galapagos appoints Michele Manto as Chief Commercial Officer

    Galapagos is preparing to deliver its first medicine to patients Mechelen, Belgium, 23 January 2020; 22.01 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that Michele Manto was appointed Chief

  3. Fibrocor and Galapagos sign expanded collaboration in fibrosis

    Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel

  4. Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis

    Mechelen, Belgium; 13 January 2020, 7.30 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205. PINTA is a

  5. Gilead holds 25.84% of Galapagos shares

    Mechelen, Belgium; 9 January 2020; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data lower than expectations released June 28, 2018.
GLPG2737 - PELICAN
Adult CF patients who are homozygous for the Class II F508del mutation
Phase 2 trial initiation announced July 5, 2017.
Filgotinib
Non-infectious uveitis
Phase 2b data due 2H 2020.
GLPG1972 - ROCCELLA
Osteoarthritis
Phase 2 trial did not meet primary endpoint.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib
Psoriatic arthritis
Phase 2a postive top-line data released November 20, 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 3 trial initiation announced December 17, 2018.
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 enrolment to be completed 3Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
NDA filing announced December 19, 2019.
Filgotinib
Rheumatoid arthritis (RA)
Phase 2 trial halted due to futility - October 28, 2019.
MOR106 IGUANA
Atopic dermatitis
Phase 2 completion of enrolment announced January 13, 2020.
GLPG1205 - PINTA
Idiopathic pulmonary fibrosis (IPF)
Phase 2 completion of enrolment announced December 5, 2019. Top-line data due 2H 2020.
GLPG1690 - NOVESA
Systemic sclerosis
Phase 1 data due 2020.
GLPG3312
Healthy volunteers
Phase 1 trial initiation announced September 24, 2019.
GLPG3970
Psoriasis

Latest News

  1. Orphan Drug Designation for GLPG1690 in systemic sclerosis

    Mechelen, Belgium; 29 January 2020, 8.00 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces today that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted

  2. Galapagos appoints Michele Manto as Chief Commercial Officer

    Galapagos is preparing to deliver its first medicine to patients Mechelen, Belgium, 23 January 2020; 22.01 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that Michele Manto was appointed Chief

  3. Fibrocor and Galapagos sign expanded collaboration in fibrosis

    Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel

  4. Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis

    Mechelen, Belgium; 13 January 2020, 7.30 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205. PINTA is a

  5. Gilead holds 25.84% of Galapagos shares

    Mechelen, Belgium; 9 January 2020; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian

  6. Galapagos to present at 38th Annual J.P. Morgan Healthcare Conference

    Mechelen, Belgium; 9 January 2020, 22.01 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) will participate in the 38th Annual J.P. Morgan Healthcare Conference on January 14-16, 2020. Bart Filius, COO &

  7. Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME

    Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME                                                         THR-687 is a potent pan-RGD integrin antagonist in

  8. Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment

    Foster City, Calif., and Mechelen, Belgium; 19 December 2019, 22.30 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that its collaboration partner, Gilead Sciences, Inc. (NASDAQ:GILD) has submitted

  9. Galapagos completes recruitment of NOVESA trial in systemic sclerosis

    Mechelen, Belgium; 5 December 2019, 22.01 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG) has completed recruitment for the NOVESA Phase 2 clinical trial with GLPG1690. NOVESA is a double-blind,

  10. Galapagos increases share capital through warrant exercises

    Mechelen, Belgium; 25 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 95,180 new

  11. Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors

    Entrepreneurial leader brings expertise growing biotech platform companies as former CEO of Editas Medicine and Avila Therapeutics Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new

  12. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 18 November 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a new transparency notification from Wellington Management Group LLP. Pursuant to Belgian

  13. Transparency notification – Gilead holds 25.10% of Galapagos shares

    Mechelen, Belgium; 13 November 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian

  14. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  15. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  16. New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional

  17. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  18. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  19. Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

    Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ:GILD), delivered an exercise notice to Galapagos NV ((Euronext &, NASDAQ:GLPG) in

  20. Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

    Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ:GILD), delivered an exercise notice to Galapagos NV ((Euronext &, NASDAQ:GLPG) in

  21. GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif. and

  22. Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases Gilead Sciences, Inc. (NASDAQ:GILD)

  23. GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif. and

  24. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  25. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  26. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  27. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  28. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  29. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  30. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  31. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  32. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a new transparency notification from Wellington Management Group LLP. Pursuant to

  33. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a new transparency notification from Wellington Management Group LLP. Pursuant to

  34. Solid third quarter 2019 performance with strong balance sheet for continued R&D growth

    First nine month financial results: Group revenues of €752.5 millionOperating profit of €393.0 millionNet profit of €265.3 millionCash and cash equivalents on 30 Sept 2019 of €5.6 billion Established unique

  35. Solid third quarter 2019 performance with strong balance sheet for continued R&D growth

    First nine month financial results: Group revenues of €752.5 millionOperating profit of €393.0 millionNet profit of €265.3 millionCash and cash equivalents on 30 Sept 2019 of €5.6 billion Established unique

  36. Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral,

  37. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  38. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  39. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Wellington Management Group LLP. Pursuant to

  40. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Wellington Management Group LLP. Pursuant to

  41. Galapagos initiates Phase 1 trial for second Toledo compound

    Second generation compound of novel target class with dual action in inflammatory disordersDiscovered and validated on Galapagos' target discovery platform Mechelen, Belgium; 24 September 2019, 22.01 CET – Galapagos

  42. Galapagos initiates Phase 1 trial for second Toledo compound

    Second generation compound of novel target class with dual action in inflammatory disordersDiscovered and validated on Galapagos' target discovery platform Mechelen, Belgium; 24 September 2019, 22.01 CET – Galapagos

  43. Invitation to the special and extraordinary shareholders' meetings

    Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) invites its shareholders to a special and extraordinary shareholders' meeting. On 14 July 2019,

  44. Invitation to the special and extraordinary shareholders' meetings

    Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) invites its shareholders to a special and extraordinary shareholders' meeting. On 14 July 2019,

  45. Transparency notification

    Mechelen, Belgium; 19 september 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Sands Capital Management, LLC. Pursuant to Belgian

  46. Galapagos increases share capital through warrant exercises

    Mechelen, Belgium; 19 September 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 301,745

  47. Galapagos increases share capital through warrant exercises

    Mechelen, Belgium; 19 September 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 301,745

  48. Transparency notification

    Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian

  49. Transparency notification

    Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian

  50. Transparency notification – Gilead holds 22% of Galapagos shares

    Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian

  51. Transparency notification – Gilead holds 22% of Galapagos shares

    Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian